Document Detail


Biologic therapies for juvenile arthritis.
MedLine Citation:
PMID:  12598373     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A group of therapies with exciting potential has emerged for children and young people with severe juvenile idiopathic arthritis (JIA) uncontrolled by conventional disease modifying drugs. Theoretical understanding from molecular biologic research has identified specific targets within pathophysiological pathways that control rheumatoid arthritis (RA) and JIA. This review identifies the pathways of autoimmunity to begin to show how biologic agents have been produced to replicate, mimic, or block culpable molecules and so promote or inhibit cellular activity or proliferation. Of these agents, cytokine antagonists have shown greatest promise, and early clinical studies of tumour necrosis factor (TNF) blockade have identified dramatic clinical benefit in many children with JIA. However, as will also be discussed, overlap of pathways within a complex immune system makes clinical response unpredictable and raises additional ethical and administrative concerns.
Authors:
N Wilkinson; G Jackson; J Gardner-Medwin
Related Documents :
19105503 - Primary prophylaxis in children with haemophilia.
12788113 - Factors related to severe uveitis at diagnosis in children with juvenile idiopathic art...
3533023 - Liver transplantation in children: experience with the development of an australian pil...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Archives of disease in childhood     Volume:  88     ISSN:  1468-2044     ISO Abbreviation:  Arch. Dis. Child.     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-02-24     Completed Date:  2003-03-18     Revised Date:  2010-09-14    
Medline Journal Info:
Nlm Unique ID:  0372434     Medline TA:  Arch Dis Child     Country:  England    
Other Details:
Languages:  eng     Pagination:  186-91     Citation Subset:  AIM; IM    
Affiliation:
Department of Rheumatology, Great Ormond Street Hospital, London, UK. petherton@clara.co.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Antibodies, Monoclonal / adverse effects,  therapeutic use
Antirheumatic Agents / adverse effects,  therapeutic use
Arthritis, Juvenile Rheumatoid / immunology,  therapy*
Autoimmunity / immunology
Biological Therapy / methods*
Child
Cytokines / therapeutic use
Humans
Immunoglobulin G / adverse effects,  therapeutic use
Interleukins / therapeutic use
Randomized Controlled Trials as Topic / ethics
Receptors, Tumor Necrosis Factor / therapeutic use
Risk Factors
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Cytokines; 0/Immunoglobulin G; 0/Interleukins; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 185243-69-0/TNFR-Fc fusion protein
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The power and prospects of fluorescence microscopies and spectroscopies.
Next Document:  Intra-articular corticosteroid injections in juvenile idiopathic arthritis.